May 17, 2023 11:13 AM EDT R&D Tyler Patchen News Reporter X4 Pharmaceuticals lifted the veil on more positive data from its Phase III study of mavorixafor as a treatment of WHIM syndrome, a rare immunodeficiency disorder that puts patients at higher risk of sometimes fatal bacterial infections. The Boston-based biotech’s drug hit the primary...